Alexander Mueller

Dr. Alexander Mueller

University of Queensland, Brisbane, Australia
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
Irina VetterIrina Vetter
Irina Vetter
JDJennifer R. Deuis
Jennifer R. Deuis
Alexander MuellerAlexander Mueller
Alexander Mueller
MIMathilde R. Israel
Mathilde R. Israel
HSHana Starobova
Hana Starobova
MMMehdi Mobli
Mehdi Mobli

8 November 2023 in Nanomaterials
Verified
Journal Article
Open access
PDF file
Johana Janina Zuñiga MirandaJohana Janina Zuñiga Miranda
Johana Janina Zuñiga Miranda
Julio Esteban GuerraJulio Esteban Guerra
Julio Esteban Guerra
Alexander MuellerAlexander Mueller
Alexander Mueller
ARArianna Mayorga Ramos
Arianna Mayorga Ramos
Saskya CarreraSaskya Carrera
Saskya Carrera
Linda GuamanLinda Guaman
Linda Guaman
The rise of antimicrobial resistance caused by inappropriate use of these agents in various settings has become a global health threat. Nanotechnology offers the potential for the synthesis of nanoparticles (NPs) with antimicrobial activity, such as iron oxide nanoparticles (IONPs). The use of IONPs is a promising way to overcome antimicrobial resistance or pathogenicity because of their ability to interact with several biological molecules and to inhibit microbial growth. In this review, we outline the pivotal findings over the past decade concerning methods for the green synthesis of IONPs using bacteria, fungi, plants, and organic waste. Subsequently, we delve into the primary challenges encountered in green synthesis utilizing diverse organisms and organic materials. Furthermore, we compile the most common methods employed for the characterization of these IONPs. To conclude, we highlight the applications of these IONPs as promising antibacterial, antifungal, antiparasitic, and antiviral agents.

7 September 2018 in Science Advances
Verified
Journal Article
Open access
PDF file
Samuel RobinsonSamuel Robinson
Samuel Robinson
Alexander MuellerAlexander Mueller
Alexander Mueller
DCDaniel Clayton
Daniel Clayton
HSHana Starobova
Hana Starobova
Brett HamiltonBrett Hamilton
Brett Hamilton
EUEivind A. B. Undheim
Eivind A. B. Undheim
Ants (Hymenoptera: Formicidae) are diverse and ubiquitous, and their ability to sting is familiar to many of us. However, their venoms remain largely unstudied. We provide the first comprehensive characterization of a polypeptidic ant venom, that of the giant red bull ant, Myrmecia gulosa. We reveal a suite of novel peptides with a range of posttranslational modifications, including disulfide bond formation, dimerization, and glycosylation. One venom peptide has sequence features consistent with an epidermal growth factor fold, while the remaining peptides have features suggestive of a capacity to form amphipathic helices. We show that these peptides are derived from what appears to be a single, pharmacologically diverse, gene superfamily (aculeatoxins) that includes most venom peptides previously reported from the aculeate Hymenoptera. Two aculeatoxins purified from the venom were found to be capable of activating mammalian sensory neurons, consistent with the capacity to produce pain but via distinct mechanisms of action. Further investigation of the major venom peptide MIITX1-Mg1a revealed that it can also incapacitate arthropods, indicative of dual utility in both defense and predation. MIITX1-Mg1a accomplishes these functions by generating a leak in membrane ion conductance, which alters membrane potential and triggers neuronal depolarization. Our results provide the first insights into the evolution of the major toxin gene superfamily of the aculeate Hymenoptera and provide a new paradigm in the functional evolution of toxins from animal venoms.

3 March 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
HSHana Starobova
Hana Starobova
MMMercedes Monteleone
Mercedes Monteleone
CAChristelle Adolphe
Christelle Adolphe
LBLena Batoon
Lena Batoon
CSCheyenne J. Sandrock
Cheyenne J. Sandrock
Irina VetterIrina Vetter
Irina Vetter
Vincristine is an important component of many regimens used for pediatric and adult malignancies, but it causes a dose-limiting sensorimotor neuropathy for which there is no effective treatment. This study aimed to delineate the neuro-inflammatory mechanisms contributing to the development of mechanical allodynia and gait disturbances in a murine model of vincristine-induced neuropathy, as well as to identify novel treatment approaches. Here, we show that vincristine-induced peripheral neuropathy is driven by activation of the NLRP3 inflammasome and subsequent release of interleukin-1β from macrophages, with mechanical allodynia and gait disturbances significantly reduced in knockout mice lacking NLRP3 signaling pathway components, or after treatment with the NLRP3 inhibitor MCC950. Moreover, treatment with the IL-1 receptor antagonist anakinra prevented the development of vincristine-induced neuropathy without adversely affecting chemotherapy efficacy or tumor progression in patient-derived medulloblastoma xenograph models. These results detail the neuro-inflammatory mechanisms leading to vincristine-induced peripheral neuropathy and suggest that repurposing anakinra may be an effective co-treatment strategy to prevent vincristine-induced peripheral neuropathy.

1 December 2017 in Neuropharmacology
Verified
Journal Article
Closed access
JDJennifer R. Deuis
Jennifer R. Deuis
Alexander MuellerAlexander Mueller
Alexander Mueller
MIMathilde R. Israel
Mathilde R. Israel
Irina VetterIrina Vetter
Irina Vetter